Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is Danaher Corporation (DHR) Halal?

PASS

Danaher Corporation · NYSE: DHR · Healthcare

The short answer

Yes — Danaher (DHR) passes this Shariah stock screen on all three gates. Its business is life sciences, biotechnology and diagnostics — Cytiva bioprocessing, Leica Microsystems, SCIEX, Beckman Coulter diagnostics, Cepheid, Radiometer — with no alcohol, gambling, tobacco, weapons, conventional-finance or other haram revenue lines (the dental, industrial and environmental businesses were spun off as Envista, Fortive and Veralto). Financials also pass: debt of $26,558M (Q2 2026 10-Q, SEC CIK 313616) is about 17.84% of its ~$148.85B market cap (702,900,000 shares × $211.76, October 1, 2026), below the ~33% ceiling; FY2025 interest income of $30M is 0.12% of FY2025 revenue ($24,568M), below the 5% ceiling. Third parties agree where they rate it: Musaffa classifies DHR HALAL and ShariaPortfolio calls it compliant (5/5 standards); Zoya's page exists but its auto-generated text is contradictory on the headline rating. This is a factual screen, not a religious ruling — consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

Danaher Corporation (NYSE: DHR), headquartered in Washington, D.C. (~60,000 associates), is a global life sciences and diagnostics company reporting three segments: Biotechnology (~$7.3B 2025 sales — Cytiva bioprocessing and discovery, Aldevron, IDT genomics), Life Sciences (~$7.3B — Leica Microsystems, SCIEX mass spectrometry, Beckman Coulter Life Sciences, Phenomenex) and Diagnostics (~$10.0B — Beckman Coulter Diagnostics, Cepheid, Leica Biosystems, Radiometer). In June 2026 it closed the ~$9.8B cash acquisition of Masimo (pulse oximetry, patient monitoring), folded into Diagnostics. Earlier spin-offs that left the company: Fortive (2016), Envista dental (2019), Veralto (Sept 2023). Business-screen implication (factual): all current segments are scientific instruments, consumables, reagents and healthcare diagnostics — no alcohol, gambling, tobacco, weapons, conventional finance or other haram business lines. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per Danaher's Q2 2026 Form 10-Q (filed July 21, 2026; SEC CIK 313616), total debt was $26,558M — LongTermDebt $26,558M (noncurrent $25,147M + current $1,411M), up from $18,418M at FY2025 year-end after the ~$9.8B Masimo cash acquisition closed June 10, 2026. Against a market cap of about $148.85B (702,900,000 shares × $211.76, October 1, 2026 — price down 4.4% that day on the announced CEO succession to Julie Sawyer Montgomery), debt ÷ market cap is about 17.84% — below the ~33% ceiling. Cash and equivalents of about $4.35B is about 2.92% of market cap. The debt gate passes. Facts only.

Gate 3 — Non-compliant income: PASS

Danaher's FY2025 Form 10-K (filed February 24, 2026) reports interest income of $30M (XBRL 'InvestmentIncomeInterest' tag) against FY2025 revenue of $24,568M — about 0.12% of revenue, well below the 5% non-compliant income ceiling. The broadest verifiable figure (interest investment income) was used; H1 2026 shows $88M interest income vs $12,216M revenue (0.72%), also below the ceiling. The income gate passes. Facts only.

Key figures used

Frequently asked questions

What does Danaher do?

Danaher (NYSE: DHR), headquartered in Washington, D.C., is a global life sciences and diagnostics company (~60,000 associates) serving pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers. It reports three segments: Biotechnology (~$7.3B, 2025 sales — Cytiva bioprocessing and discovery, Aldevron, IDT genomics), Life Sciences (~$7.3B — Leica Microsystems, SCIEX mass spectrometry, Beckman Coulter Life Sciences, Phenomenex) and Diagnostics (~$10.0B — Beckman Coulter Diagnostics, Cepheid, Leica Biosystems, Radiometer). In June 2026 it closed the ~$9.8B cash acquisition of Masimo (pulse oximetry and patient monitoring), which joined Diagnostics. Earlier spin-offs: Fortive (2016), Envista dental (2019), Veralto environmental & applied solutions (Sept 2023).

Why does Danaher pass this Shariah stock screen?

Danaher passes all three gates. Gate 1: its three segments are life sciences, biotechnology and diagnostics — instruments, consumables, reagents and software for research and healthcare — with no alcohol, gambling, tobacco, weapons, conventional-finance or other haram business lines in its own revenue (facts only; this is a screen, not a religious ruling — consult a qualified scholar for personal rulings). Gate 2: debt of $26,558M is about 17.84% of its ~$148.85B market cap, below the ~33% ceiling. Gate 3: FY2025 interest income of $30M is about 0.12% of FY2025 revenue ($24,568M), below the 5% ceiling.

What is Danaher's interest-bearing debt ratio?

Per Danaher's Q2 2026 Form 10-Q (filed July 21, 2026; SEC CIK 313616), total debt was $26,558M (LongTermDebt $26,558M incl. current; noncurrent $25,147M + current $1,411M) — up from $18,418M at FY2025 year-end after the ~$9.8B Masimo cash acquisition closed June 10, 2026. Against a market cap of about $148.85B (702,900,000 shares × $211.76, October 1, 2026), debt ÷ market cap is about 17.84% — below the ~33% ceiling. Cash and equivalents of about $4.35B is about 2.92% of market cap. The debt gate passes. Facts only.

What is Danaher's non-compliant income ratio?

Danaher's FY2025 Form 10-K (filed February 24, 2026) reports interest income of $30M against FY2025 revenue of $24,568M — about 0.12% of revenue, well below the 5% non-compliant income ceiling. Using the broadest verifiable line (the XBRL 'InvestmentIncomeInterest' tag: $30M FY2025; $88M for H1 2026 vs $12,216M H1 revenue = 0.72%), the income gate passes comfortably in both periods. Facts only.

Do Zoya, Musaffa, or ShariaPortfolio cover Danaher?

Zoya covers DHR: its public stock page renders contradictory auto-generated template text (simultaneously calling DHR "Shariah-compliant and therefore considered halal" and "Shariah-compliant ... not considered halal" as of September 2026), but does cite interest income of $30M / 0.12% of FY2025 revenue — honestly reported as inconclusive on the headline rating. Musaffa covers DHR (musaffa.com/stock/DHR): classified HALAL as of September 2026 per its Shariah screening methodology. ShariaPortfolio covers DHR: "Danaher Corp is Shariah Compliant. It passes 5/5 Shariah standards we screen against." None invented; this page applies the screen directly from Danaher's own SEC filings.

Sources

Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).